Takeda to sell non-core assets for $200M+ — 3 insights

Takeda reached a deal to sell a number of its over-the-counter and prescription pharmaceutical assets to Swiss pharmaceutical company Acino for more than $200 million.

What you should know:

1. Acino will acquire 30 select prescription pharmaceutical and OTC products. The assets are all located in the Near East, Middle East and Africa markets.

2. Takeda is in the process of selling non-core assets to combat the debt it took on during its acquisition of Shire. Takeda became one of the most indebted drugmakers in the world after it acquired Shire.

3. The companies expect the transactions will close in the fourth quarter of 2019.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast